Phase II efficacy study on-goingInovio continues patient recruitment for its phase II study of VGX-3100, which is designed to enroll 148 patients with cervical dysplasia at multiple study centers. This randomized, double-blinded, placebo-controlled study will assess regression of cervical lesions from CIN 2/3 or CIN 3 to CIN 1 or complete regression of the lesions. The secondary endpoint is to assess the clearance of HPV 16 or 18. Subjects will also be monitored for tolerability and safety. Inovio expects results from this trial late next year. See the HPV-003 clinical trial protocol.
Inovio Pharmaceuticals' Cancer Vaccine Demonstrates For 1st Time That A DNA-Based Therapeutic Vaccine Can Produce Immune Responses To Kill Target Cells
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.